Conjugates and prodrugs for treating cancer and inflammatory diseases
US10293021B2 · kind B2 · utility
0Cited by
1References
17Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Feb 6, 2015 |
| Grant date | May 21, 2019 |
| Priority date | — |
| Expiry date | Apr 9, 2035 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to the field of cancer and inflammatory diseases. More particularly, it aims to provide, for these purposes, novel conjugated forms of active ingredients belonging to the dolastatin family and having the formula as follows:It is also directed towards prodrug forms of these conjugates.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.